Tranexamic acid

Generic Name
Tranexamic acid
Brand Names
Cyklokapron, Lysteda
Drug Type
Small Molecule
Chemical Formula
C8H15NO2
CAS Number
1197-18-8
Unique Ingredient Identifier
6T84R30KC1
Background

Tranexamic acid is a synthetic derivative of lysine used as an antifibrinolytic in the treatment and prevention of major bleeding. It possesses a similar mechanism of action to aminocaproic acid but is approximately 10-fold more potent.

It was first patented in 1957 and received its initial US approval in 1986.

Indication

Taken orally, tranexamic acid is indicated for the treatment of hereditary angioedema, cyclic heavy menstrual bleeding in premenopausal females, and other instances of significant bleeding in the context of hyperfibrinolysis. Given intravenously, tranexamic acid is indicated for short-term use (2-8 days) in patients with hemophilia to prevent or reduce bleeding following tooth extraction.

Associated Conditions
Bleeding, Heavy Menstrual Bleeding, Hereditary Angioedema (HAE)
Associated Therapies
-
Clinical Trials
Related News

Intra-articular Tranexamic Acid in the Reduction of Blood Transfusions in Primary Total Hip and Total Knee Arthroplasty

Phase 2
Completed
Conditions
Osteoarthritis
Interventions
Other: Placebo
Drug: Tranexamic Acid
First Posted Date
2015-03-20
Last Posted Date
2017-04-10
Lead Sponsor
Orthopaedic Innovation Centre
Target Recruit Count
140
Registration Number
NCT02393963
Locations
🇨🇦

Concordia Hospital, Winnipeg, Manitoba, Canada

Comparison of Topical Versus Intravenous Tranexamic Acid in TKA

Phase 3
Completed
Conditions
Total Blood Loss
Interventions
Drug: normal saline
Drug: Tranexamic Acid
First Posted Date
2015-03-19
Last Posted Date
2018-04-04
Lead Sponsor
Shanghai Jiao Tong University School of Medicine
Target Recruit Count
174
Registration Number
NCT02393300
Locations
🇨🇳

Orthopedic Department of Ruijin hospital, Shanghai, Shanghai, China

Clinical Trial Comparing Tranexamic Acid (TXA) With Aquamantys Sealer in Total Knee Arthroplasty (TKA)

First Posted Date
2015-02-27
Last Posted Date
2017-01-16
Lead Sponsor
Eastern Maine Medical Center
Target Recruit Count
127
Registration Number
NCT02374398
Locations
🇺🇸

Eastern Maine Medical Center, Bangor, Maine, United States

TXA in the EMS on the Helicopter and the Ambulance

Phase 4
Conditions
Bleeding
Interventions
Drug: Tranexamic Acid
First Posted Date
2015-02-03
Last Posted Date
2015-02-03
Lead Sponsor
University of Zurich
Target Recruit Count
50
Registration Number
NCT02354885
Locations
🇨🇭

University Hospital Zurich, Division of Anaesthesiology, Zurich, ZH, Switzerland

🇨🇭

USZ, Zurich, Switzerland

Efficacy of Tranexamic Acid in Reducing Blood Loss During and After Caesarean Section

First Posted Date
2015-01-29
Last Posted Date
2015-02-10
Lead Sponsor
Ain Shams University
Target Recruit Count
100
Registration Number
NCT02350179
Locations
🇪🇬

Ain Shams University, Cairo, Egypt

Low Dose Peri- Operative Intra Venous Teranexamic Acid Reduces Blood Loss After Total Knee Arthroplasty: A Double Blind Randomized Placebo Controlled Clinical Trial

Not Applicable
Completed
Conditions
Knee Arthroplasty, Total
Interventions
Drug: Normal saline
Drug: Tranexamic Acid
First Posted Date
2014-12-30
Last Posted Date
2016-07-22
Lead Sponsor
Isfahan University of Medical Sciences
Target Recruit Count
90
Registration Number
NCT02327117
Locations
🇮🇷

Amin Nemati, Isfahan, Iran, Islamic Republic of

Evaluation of the Pharmacokinetic Profile of Tranexamic Acid, After Injection in a Knee Neo-articulation.

Early Phase 1
Completed
Conditions
Knee Prosthesis
Interventions
Drug: Tranexamic Acid
Drug: Adrenalin
First Posted Date
2014-12-18
Last Posted Date
2018-01-19
Lead Sponsor
Brugmann University Hospital
Target Recruit Count
14
Registration Number
NCT02319915
Locations
🇧🇪

CHU Brugmann, Brussels, Belgium

Tranexamic Acid to Reduce Blood Loss in Spine Trauma Surgery

First Posted Date
2014-12-11
Last Posted Date
2024-04-15
Lead Sponsor
Columbia University
Target Recruit Count
252
Registration Number
NCT02314988
Locations
🇺🇸

University of California San Francisco Medical Center, San Francisco, California, United States

🇺🇸

Madigan Army Medical Center, Tacoma, Washington, United States

🇺🇸

Duke University Medical Center, Durham, North Carolina, United States

and more 2 locations

Comparison of Topical and Intravenous Tranexamic Acid in Total Hip Arthroplasty

Phase 3
Completed
Conditions
Blood Loss
Interventions
Drug: 0.9% sodium chloride
Drug: tranexamic acid
First Posted Date
2014-12-09
Last Posted Date
2015-12-02
Lead Sponsor
Shanghai Jiao Tong University School of Medicine
Target Recruit Count
173
Registration Number
NCT02312440
Locations
🇨🇳

Orthopedic Department of Ruijin hospital, Shanghai, Shanghai, China

Tranexamic Acid for Preventing Postpartum Haemorrhage Following a Vaginal Delivery

First Posted Date
2014-11-27
Last Posted Date
2017-09-06
Lead Sponsor
University Hospital, Angers
Target Recruit Count
4079
Registration Number
NCT02302456
Locations
🇫🇷

Angers University Hospital, Angers, France

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy